Clinical trial NCT05397041: A 3-Part Study to Evaluate the Safety, Tolerability, PK, and Food Effect of BMB-101 in Healthy Volunteers
Official title: A Randomized, Double-Blind, Placebo-Controlled, Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of BMB-101 in Fed and Fasted Adult Healthy Human Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Bright Minds Biosciences Pty Ltd
Sponsor class: INDUSTRY
First posted: 2022-05-31
Enrollment: 81
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Intervention model description: SAD, FE, MAD, dose escalating
Primary purpose: TREATMENT

Brief summary: This study is designed as a single centre, double blind, placebo controlled, randomized, SAD/FE/MAD, safety, tolerance and PK study of BMB-101 in healthy adult subjects. The study will be conducted as a 3-part study.

Detailed description: This study is designed as a 3-part study:

Part 1 is designed as single ascending dose (SAD) escalation study investigating 4 dose levels. Each cohort will consist of participants to be randomly assigned to receive a blinded oral dose of BMB-101 or placebo.

Part 2 is designed as a randomized, orally administered, single-dose, two-treatment (fed vs fasted), two-period, two-sequence crossover to assess the effects of a standard high-fat breakfast on PK of BMB-101.

Part 3 is designed as a multiple ascending dose (MAD) escalation study investigating up to 4 dose levels. Subjects will be randomized to receive double-blind treatment of BMB-101 or matching placebo twice daily for 7 days.

Eligibility criteria: Key Inclusion Criteria:

1. Subject must be aged between 18 and 55 years (both inclusive).
2. Healthy subjects with no clinically significant screening results.
3. Body mass index (BMI) 18.0 to 32.0 kg/m².
4. Males and non pregnant females willing to use contraceptives consistent with local regulations from screening through 3 months after the last dose of study medication.
5. Agree to frequent blood and urine sampling during the course of the study.
6. Agree to be confined in the study unit and follow study procedures.

Key Exclusion Criteria:

1. Subjects with unstable or severe illness as indicated on medical history, physical examination, or clinical laboratory, vital signs, and electrocardiograms (ECGs) evaluations, or in the opinion of the Investigator.
2. Subjects with reported history within past 6 months of, or current treatment for, any GI disease that may impact the absorption of an oral drug for example gastroesophageal reflux disorder, peptic ulcer disease, inflammatory bowel disease.
3. Subjects with a history of seizures other than febrile seizures as a child.
4. Subjects with history of or current glucose intolerance; or with history of gestational diabetes.
5. Subjects with lifetime history of suicidal behavior or with lifetime history of suicidal ideation as indicated by the Columbia-Suicide Severity Rating Scale (C-SSRS)
6. Subjects with any use of or intent to use any medications, including prescription, over-the-counter (OTC), herbal preparations, or vitamin/mineral supplementation, other than study medications, from 7 days prior to first dose through follow-up visit.
7. Female subjects with a positive pregnancy test at Screening or Day -1 or who are breastfeeding.
8. Subjects who have used more than 5 cigarettes, cigars, or nicotine-containing products per month within 6 months prior to first study dose, or plan to use them through completion of the follow-up visit.
9. Subjects with a positive drug screen for illegal drugs including cannabis at Screening or Day -1.

Primary outcomes:
measure: Number of Treatment-emergent Adverse Events
timeFrame: Baseline up to Follow Up/End of Treatment visit, an average of 8 months.
measure: Change in Columbia-Suicide Severity Rating Scale (C-SSRS) Response
timeFrame: Administered at each of the following visits in Part 3: Screening, Clinic Discharge, and Follow-up/Early Withdrawal.
Secondary outcomes:
measure: Pharmacokinetic Assessment
timeFrame: Day 1 through End of Dosing Period.
Other outcomes:
Locations:
city: Adelaide
country: Australia
facility: CMAX Clinical Research
state: South Australia
Study officials:
affiliation: CMAX Clinical Research
name: Michele De Sciscio
role: PRINCIPAL_INVESTIGATOR
References: